Bank Julius Baer & Co
HEPA

Bank Julius Baer & Co’s Hepion Pharmaceuticals HEPA Stock Holding History

Bank Julius Baer & Co’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13
Closed -$26K – 829
2021
Q2 		$26K Hold
13
– – ﹤0.01% 738
2021
Q1 		$24K Buy
13
+5
+63% +$11K ﹤0.01% 733
2020
Q4 		$18K Buy
+8
New +$20.7K ﹤0.01% 753

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank Julius Baer & Co's HEPA Position: Q3 2021 in Review

Bank Julius Baer & Co sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 13 shares — an estimated $26K sold.

Bank Julius Baer & Co first reported a position in HEPA in Q4 2020 and held it in 3 quarters. The position peaked at $26K in Q2 2021. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Bank Julius Baer & Co reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 13 Hepion Pharmaceuticals shares in Q3 2021, an estimated $26K.
  • Bank Julius Baer & Co first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Hepion Pharmaceuticals position peaked at $26K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Bank Julius Baer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.